REG - Poolbeg Pharma PLC - Director/PDMR Shareholding

Poolbeg PharmaAnnouncement

Wed 08:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250625:nRSY2637Oa&default-theme=true

RNS Number : 2637O  Poolbeg Pharma PLC  25 June 2025

Poolbeg Pharma plc

 

Director Dealing

25 June 2025 - Poolbeg Pharma (http://www.poolbegpharma.com)  (AIM: POLB,
'Poolbeg' or the 'Company'), a clinical-stage biopharmaceutical company
focussed on the development of innovative medicines to address unmet medical
needs, confirms that as announced  on 20 May 2025, Mr Cathal Friel, Executive
Chair and PDMR of the Company, participated in the Fundraising subscribing for
4,000,000 new Ordinary Shares at a price of 2.5p per share (the Issue Price).
 Following the AGM earlier this week, the New Ordinary Shares issued pursuant
to the Fundraising were admitted to trading at 8am today.

 

Following this transaction, Cathal Friel holds a total of 41,219,757 ordinary
shares in the Company, representing approximately 5.91% of the Company's
issued share capital.

 

 

Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them:

 

 1   Details of the person discharging managerial responsibilities/person closely
     associated
 a.  Name of PDMR                                                 Cathal Friel
 2   Reason for notification

 a.  Position/Status                                              Executive Chair
 b.  Initial notification/                                        Initial notification

     Amendment
 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a.  Name                                                         Poolbeg Pharma plc
 b.  LEI                                                          213800UZ8WJLWYHBFL52
 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a.  Description of the financial instrument, type of instrument  Ordinary shares of 0.02 pence each

     Identification Code

                                                                  ISIN GB00BKPG7Z60
 b.  Nature of the transaction                                    Purchase of ordinary shares in connection with the fundraising initially
                                                                  announced on 20 May 2025.
 c.  Price(s) and volume(s)                                       Price(s)                               Volume(s)
     2.5p                                                                                                4,000,000
 d.  Aggregated information

                                                                  As in 4c) above

     - Aggregated Volume

     - Price
 e.  Date of the transaction                                      25 June 2025
 f.  Place of the transaction                                     London Stock Exchange, AIM Market (XLON)

 

 

Enquiries

 

 Poolbeg Pharma Plc                                              +44 (0) 207 183 1499

 Jeremy Skillington, CEO                                         ir@poolbegpharma.com

 Ian O'Connell, CFO

 Cavendish Capital Markets Ltd (NOMAD & Joint Broker)            +44 (0) 207 220 0500

 Geoff Nash, Trisyia Jamaludin (Corporate Finance)

 Nigel Birks (Life Science Specialist Sales)

 Harriet Ward (ECM)

  
 Shore Capital Stockbrokers Ltd (Joint Broker)                   +44 (0) 207 408 4090

 David Coaten, Harry Davies-Ball (Corporate Advisory)

Malachy McEntyre, Isobel Jones (Corporate Broking)

 J&E Davy (Joint Broker)                                         +353 (0) 1 679 6363

 Anthony Farrell, Niall Gilchrist

  
 Optimum Strategic Communications                                +44 (0) 208 078 4357

 Nick Bastin, Vici Rabbetts, Elena Bates                         poolbeg@optimumcomms.com (mailto:poolbeg@optimumcomms.com)

  

 

The information contained within this announcement is deemed by the Company to
constitute inside information as stipulated under the Market Abuse Regulation
("MAR") EU no.596/2014. Upon the publication of this announcement via
Regulatory Information Service ("RIS"), this inside information is now
considered to be in the public domain.

 

About Poolbeg Pharma plc

Poolbeg Pharma plc is a clinical-stage biopharmaceutical company focussed on
the development of innovative medicines to address unmet medical needs. The
Company's clinical programmes target large addressable markets including
cancer immunotherapy-induced Cytokine Release Syndrome ("CRS") and metabolic
conditions such as obesity with the development of an oral encapsulated GLP-1.

 

For more information, please go to www.poolbegpharma.com
(https://www.poolbegpharma.com)  or follow us on Twitter
(https://twitter.com/PoolbegPharma) and LinkedIn
(https://www.linkedin.com/company/poolbeg-pharma) @PoolbegPharma.

 

Forward-Looking Statements

This announcement may contain forward-looking statements and the words
"expect", "anticipate", "intends", "plan", "estimate", "aim", "forecast",
"project" and similar expressions (or their negative) identify certain of
these forward-looking statements. The forward-looking statements in this
announcement are based on numerous assumptions and Poolbeg's present and
future business strategies and the environment in which Poolbeg expects to
operate in the future. Forward-looking statements involve inherent known and
unknown risks, uncertainties and contingencies because they relate to events
and depend on circumstances that may or may not occur in the future and may
cause the actual results, performance or achievements to be materially
different from those expressed or implied by such forward-looking statements.
These statements are not guarantees of future performance or the ability to
identify and consummate investments. Many of these risks and uncertainties
relate to factors that are beyond Poolbeg's ability to control or estimate
precisely, such as future market conditions, currency fluctuations, the
behaviour of other market participants, the outcome of clinical trials, the
actions of regulators and other factors such as Poolbeg's ability to obtain
financing, changes in the political, social and regulatory framework in which
Poolbeg operates or in economic, technological or consumer trends or
conditions. Past performance should not be taken as an indication or guarantee
of future results, and no representation or warranty, express or implied, is
made regarding future performance. No person is under any obligation to update
or keep current the information contained in this announcement or to provide
the recipient of it with access to any additional relevant information.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHFFFSIRTISFIE